In a regulatory filing last night, Karyopharm disclosed that CFO Michael Mason sold 4,205 shares at $1.59 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KPTI:
- Biotech Alert: Searches spiking for these stocks today
- Morphosys interest highlights Karyopharm’s opportunity in MF, say RBC Capital
- Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
- Karyopharm sees FY23 revenue $145.9M, consensus $150.03M
- Karyopharm sees Q4 revenue $33.6M, consensus $37.64M
